The 10-week IPO itch: Your locked-up stock is half as valuable. What now?

Menlo Therapeutics' stock was flying high Friday. Then results of a clinical trial hit and the stock dropped more than $9 under its late January IPO price. But a subset of investors could do nothing but watch, locked out from selling their shares.
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news